PHS73 Costs Of Pilot Programs In Chicago-Based Centers For Population Health And Health Disparities: A Case For Team-Care?  by Walton, S et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A137
Objectives: Diagnosis and monitoring of lymphoma includes lymph node assess-
ment. This study examined the association of multiple lymph node biopsies and 
health care resource use among lymphoma patients. MethOds: Patients with ≥ 2 
claims for Hodgkin lymphoma (HL) or non-Hodgkin’s (NHL) lymphoma from 1/1/06-
12/31/12 were identified from a large US claims database; the index date was the 
first lymphoma claim date. Patients were retained if continuously enrolled in the 
health plan for ≥ 12 months before and after the index date, were not diagnosed 
with lymphoma during the pre-index period or diagnosed with cancer other than 
lymphoma. Health care cost and utilization were examined during the 2-year study 
period. Indication of receipt of biopsy included ≥ 1 claim for a lymph node biopsy 
(core needle, fine needle, surgical, other), pathology, or tumor excision (bone marrow 
biopsy not included). Health care cost and utilization was examined among patients 
with 0 to ≥ 3 biopsies. The cost of claims indicating biopsy was identified for each 
biopsy type. Results: 20,813 newly diagnosed lymphoma patients met all inclu-
sion criteria. 16,557 (80%) had ≥ 1 claim indicating biopsy, 12,920 (62%) had ≥ 2 and 
8,783 (42%) had ≥ 3. The percentage with an inpatient stay and ER visit was greatest 
among patients with ≥ 3 biopsies (52%, 53%) compared to patients with 2 (33%, 41%), 
1 (25%, 34%), or 0 biopsies (26%, 42%). Total health care cost was greatest among 
patients with ≥ 3 biopsies ($102,465) compared to 2 ($51,565), 1 ($25,614), or 0 biopsies 
($15,671). The cost of biopsies ranged from $307 for a fine needle biopsy to $3,296 
for a complex surgical biopsy and $12,353 for other biopsies. Biopsies involving the 
mediastinum cost $10,554 on average. cOnclusiOns: Lymphoma patients incur 
significant health care cost and utilization. Increasing the efficiency of lymph node 
diagnosis could avoid the need for repeat biopsies and reduce health care costs.
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Objectives: To measure the costs of two team-care based pilot interventions. These 
interventions are part of the Chicago-based National Institutes of Health-funded 
Centers for Population Health and Health Disparities (CPHHD) designed to improve 
health outcomes in medically underserved communities. MethOds: The data 
come from two Chicago-based CPHHD randomized controlled trials. Use of a vir-
tual team aimed at reducing depressive symptoms in older adults with depression 
(BRIGHTEN Heart) and cardio-metabolic syndrome and use of a patient navigator 
to improve diagnostic follow-up of mammography screening for breast cancer. The 
programs collected detailed data regarding service delivery and resource use. Costs 
were measured from a provider perspective. Actual time spent with patients was 
estimated in the navigator program using details on activities performed and previ-
ous time study data for those activities in similar programs. Time was converted 
to costs based on average wages reported by the Bureau of Labor Statistics (BLS) 
by occupational title. BRIGHTEN Heart involved multiple services along with time 
and travel cost estimates for each occupation and service. Results: There were 
493 patients that received patient navigator services and 16 patients in the virtual 
team-based BRIGHTEN Heart intervention. The patients were almost all minorities 
and were below average in terms of income and education. The operating cost of the 
Navigator program was $14.29 following diagnostic screening. The operating cost 
for the year of virtual team care in BRIGHTEN Heart was $753.18. cOnclusiOns: 
Costs are an important consideration for evaluating team-care based interventions 
to improve patient health in the underserved. The two programs evaluated here 
offer insight into the relatively low cost of interventions with team-care strategies 
employing allied health workers. Given the low cost of care, the programs offer 
promise of being cost effective. Future work will examine these costs in comparison 
to the effectiveness of the program.
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Objectives: To examine patient characteristics, treatment patterns, and health 
care resource utilization of patients with neuroendocrine tumors (NETs) in the 
US. MethOds: Using a US administrative claims database, commercially-insured 
adults newly diagnosed with carcinoid tumors (ICD-9-CM: 209.xx) or pancreatic 
islet cell tumors (ICD-9-CM: 157.4 and 211.7) between 07/01/2007 and 12/31/2010 
were identified (the date of the first observed diagnosis as the index date). Patients 
were required to have 6-month pre-index and 12-month post-index continuous 
enrollment. Descriptive analysis was performed to describe demographic and clini-
cal characteristics, treatment patterns for NETs, and health care resource utiliza-
tion during the 12-month post-index period. Similar analysis was conducted for 
Medicare-eligible individuals with the supplemental private insurance. Results: 
This study included 3,940 commercially-insured individuals (mean age: 52.3 years; 
55.4% female) and 1,658 Medicare-eligible individuals (mean age: 74.9 years; 49.0% 
female) with NETs. In the commercial population, carcinoid syndrome (33.2%), liver 
metastasis (22.4%), and nausea/vomiting (18.2%) were most common among the 
comorbidities evaluated. While 19.5% of individuals received surgical therapy and 
17.5% received medical therapy (somatostatin analogue treatment) as the first-
line treatment, nearly two-thirds received neither of those treatments. During the 
12-month post-index period, about half of individuals had inpatient hospitalization 
and 35.4% had emergency room visits; the mean physician office visit was 19.9. 
In the Medicare population, carcinoid syndrome (27.4%), liver metastasis (20.7%), 
and diarrhea (16.1%) were the most prevalent comorbidities. While 13.2% received 
surgical therapy and 19.8% received medical therapy, over two-thirds received nei-
ther. Approximately half of individuals had inpatient hospitalization and 37.3% had 
emergency room visit during the 12-month post-index period; the mean physician 
office visit was 26.1. cOnclusiOns: This exploratory study described real world 
Based Measure-SBM) and Malmquist index with Clearances. The sum of these two 
items is corresponding to the total expenditure in the sector analysed. Output: the 
output is defined as the number of renal transplants performed by every Brazilian 
State. Results: Examining the decomposition of the Malmquist index, has that 
18 States increased the index of pure change of efficiency (Pairing) with values 
greater than 1. According to the results, 21 States have submitted an index less 
than 1, indicating an offset of the boundary of production to a lower level. The 
analysis of efficiency of Brazilian States proposed in this study indicates a need 
for a better allocation and/or application of the resources spent by the SUS in the 
area of kidney transplants. cOnclusiOns: The results of this survey suggest that 
the process of kidney transplants has presented an activity with great variability 
between States. The offer of the kidney organ becomes insufficient in these places 
to meet the demand, creating queues of waiting for a kidney transplant. The sys-
tem of kidney transplants in Brazil, in the current period, presents a number of 
surgeries that are below the population’s needs, due mainly to the lack of effective 
donations of this organ.
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Objectives: TSC is a multi-system genetic disorder that affects up to 8,000 patients 
in the UK. It is associated with non-malignant lesions throughout the body, neu-
rological manifestations, and impaired cognition. Consequently, the burden on 
patients, their families, and the health care system is thought to be substantial. 
This study assesses the real-world economic impact of TSC in the UK. MethOds: 
TSC patients were retrospectively identified between April, 1997 to March, 2012 in 
CPRD (Read: PK5.00, PK5.12) and linked Hospital Episodes Statistics (HES; ICD-10: 
Q85.1) databases. Health care encounters in the following settings were analysed: 
general practitioner (GP), inpatient, emergency room (ER) admissions and outpa-
tient. Analyses were stratified by age at time of occurrence for pediatrics (< 18 years) 
and adults (≥ 18 years). Results: A total of 341 TSC patients were identified (52% 
female; median age 14.4 years at first event). The annual rate (mean[SD]) of health 
care encounters (by person-year) was 13.7(14.3) for paediatrics and 15.6(15.3) for 
adults. Annual rates (mean[SD]) of paediatric vs. adult encounters by care setting 
was as follows: GP, 10.1(3.1) vs. 12.9(14.2); inpatient, 1.0(1.6) vs. 0.6(1.0); ER admis-
sion, 0.4(0.8) vs. 0.3(0.7); outpatient, 3.9(3.3) vs. 2.8(3.0). Neurological manifestations 
(primarily epilepsy, including infantile spasms and status eptilepticus) were most 
common in pediatrics resulting in inpatient and ER admission use in 53% and 62% 
of patients, respectively. Musculoskeletal manifestations were most common in 
adults resulting in inpatient and ER use in 31% and 33% of patients, respectively. 
Mean(SD) number of surgical procedures and tests/patient-year was 0.2(0.4) and 
0.3(0.4), respectively. MRI or CT scans were observed in 34% of pediatrics and 26% 
of adults. cOnclusiOns: Health care resource utilization rates suggest significant 
economic burden of TSC throughout life. Absence of MRI or CT procedures may 
signify deviation from recommended monitoring guidelines. Further analyses will 
quantify the cost impact of TSC on the UK health care system.
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Objectives: The aim of this study was to identify high cost sickle cell disease (SCD) 
patients (HCSPs) and analyze their cost patterns throughout lifetime and as they 
transition from pediatric to adult care. MethOds: State Medicaid data from 1997 to 
2010 were analyzed. Patients with ≥ 2 SCD diagnoses and ≥ 1 blood transfusion were 
included. HCSPs were defined as the fraction of most expensive patients account-
ing for 50% of the total yearly costs. Periodic events associated with high costs are 
likely to be responsible for high total costs. High cost events (HCEs), defined as quar-
ters with costs ≥ $33,095, corresponding to the amount separating the top 5% most 
expensive quarters observed in the sample, were analyzed. A longitudinal logistic 
regression model was used to identify factors associated with HCEs. Results: 
From a cohort of 3,208 eligible SCD patients, 449 (14%) were identified as HCSPs. 
The average yearly total cost of HCSPs was significantly higher at $108,524/year 
compared to $17,683/year for other patients. The share of the total yearly costs of 
HCSPs increased from 34.4% to 46.3% between age groups 11-15 and 16-20, reaching 
its maximum at 65.2% in the 26-30 age group. The frequency of HCEs increased by 
122.6% in the transitioning group from 0.110 HCE/year among patients aged 11-15 to 
0.244 HCE/year among patients aged 16-20. Patients were more likely to have a HCE 
during the post-transition period (adjusted odds ratio [OR]: 1.41, p= .0046) and when 
experiencing an SCD complication (OR: 3.79, p< .0001). Blood transfusions received 
during the previous quarter were associated with a lower likelihood of HCEs (OR: 
0.87, p= .0080). cOnclusiOns: In this population of Medicaid SCD patients, 14% 
were responsible for over 50% of total yearly health care costs. Directing appropriate 
and targeted interventions can help assist providers improve outcomes and lower 
health care costs in this patient population.
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